a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Conditions

Acute Myeloid Leukemia · IDH1 Gene Mutation · Ivosidenib

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Contact: Study coordinator (Su-ning Chen, M.D.) · chensuning@sina.com · +8613814881746

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic Therapy

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Phoenix, United States

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Tucson, United States

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse

Abroad (travel likely)RecruitingPHASE1

Boston, United States

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Iowa City, United States